# Adaptive Immunotherapy for Nasopharyngeal Carcinoma

> **NCT07154069** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 802 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **RADIATION:** Radical radiotherapy of nasopharynx and neck
- **DRUG:** Capecitabine
- **DRUG:** Concurrent chemoradiotherapy (cCRT)
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07154069
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-13
- **Primary completion:** 2031-09
- **Final completion:** 2033-09
- **Target enrollment:** 802 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07154069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07154069, "Adaptive Immunotherapy for Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07154069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*